Veru, Inc. (VERU) Appoints Steven B. Heymsfield as the Principal Investigator for Enobosarm Phase 2b Trial for High Quality Weight Loss

May 15, 2024 8:32 AM EDT

Veru Inc. (NASDAQ: VERU) today announced Steven B. Heymsfield, M.D., a Professor and the Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center in Baton Rouge, Louisiana, as the Principal Investigator for the Company’s Phase 2b clinical trial of enobosarm to preserve muscle while augmenting fat loss in patients receiving a GLP-1 RA for weight loss.

Dr. Heymsfield is a leading authority on body composition assessment and his research focuses primarily on human obesity, including energy balance regulation, weight loss treatments, co-morbidity effects, and development of related mathematical models. He has a long term-interest in the development of methods for evaluating body composition and the application of new technologies to the study of human metabolism.

Dr. Heymsfield received a degree in medicine from Mount Sinai School of Medicine, and he completed his internship, residency, and fellowship in pharmacology at Emory University. He then joined the Emory University School of Medicine faculty, holding positions there including Associate Professor of Medicine and Assistant Director of the NIH-funded Clinical Research Unit. Expanding on his interests in obesity and metabolism, Dr. Heymsfield next moved to Columbia University, College of Physicians and Surgeons and there he held positions as Professor of Medicine and Deputy Director, New York Obesity Research Center at St. Luke’s-Roosevelt Hospital. He and his Columbia colleagues conducted wide ranging clinical studies on obesity with a focus on energy metabolism, body composition, and pharmacologic weight control management. Prior to his Pennington Biomedical position, Dr. Heymsfield worked with Merck & Co. for 5 years, initially as Executive Director in the Obesity Group and then as Global Director of Scientific Affairs.

Dr. Heymsfield has published more than 600 peer-reviewed papers covering topics such as obesity, malnutrition, cachexia, body composition, and caloric expenditure. His contributions to the study of human nutrition led to the TOPS Award from The Obesity Society, the Rhoads Award from the American Society of Parenteral and Enteral Nutrition (ASPEN), the Robert H. Herman Memorial Award, American Society of Nutrition (ASN), the George Bray Founders Award from The Obesity Society, and he was honored for his role in the FDA ban on ephedra, receiving the 2004 NYC Mayor’s Award for Science and Technology. Dr. Heymsfield was elected Fellow of The Obesity Society in 2014, and he is an honorary member of the American Dietetic and Chilean Clinical Nutrition Associations. Dr. Heymsfield is past president of ASPEN and ASN and he is vice-president of The Obesity Society.

As the Principal Investigator for the Company’s enobosarm Phase 2b clinical trial, Dr. Heymsfield will lead the clinical trial sites. He will also participate in the study analysis and contribute to reporting the results to the FDA and scientific journals and meetings.

“I am pleased to serve as the Principal Investigator for this important Phase 2b enobosarm clinical trial. I am enthusiastic to be participating in enobosarm’s development, a medicine that has a novel established mechanism of action that has the potential to improve the quality of weight loss for these patients,” said Steven Heymsfield, MD, a Professor and the Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center in Baton Rouge, Louisiana.

"Dr. Heymsfield is an expert in body composition and obesity and an ideal clinical leader to serve as the Principal Investigator of the enobosarm Phase 2b clinical trial," said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru Inc. “Veru is proud to have Dr. Heymsfield as our partner with the enobosarm clinical trial. There is a significant unmet medical need for patients undergoing weight loss treatments with GLP-1 RAs to address the issue of muscle loss. We believe enobosarm could potentially be a great addition for patients to make their weight loss journey as healthy as possible. We look forward to enrolling this Phase 2b clinical trial expeditiously with data expected by year-end."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Changes

Related Entities

Bankruptcy, FDA